Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 28, 2024

Second-Line BRAF Inhibitor/MEK Inhibitor/Anti–PD-1 Combined Therapy in BRAF-Mutated Melanoma With CNS Metastases After First-Line Combined Targeted Therapy

Melanoma research

 

Additional Info

Melanoma research
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey
Melanoma Res. 2024 Jun 01;34(3)241-247, M Fabre, A Lamoureux, L Meunier, Q Samaran, C Lesage, C Girard, A Du Thanh, L Moulis, O Dereure

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading